Dacarbazine Citrate

Dacarbazine Citrate is a chemotherapy medication being studied in clinical trials for various types of cancer, particularly melanoma and Hodgkin lymphoma. This article explores the use of Dacarbazine Citrate in ongoing clinical trials, its potential benefits, and what patients should know about participating in these studies.

Table of Contents

What is Dacarbazine?

Dacarbazine, also known as DACARBAZINE CITRATE, is a chemotherapy medication used to treat various types of cancer[1]. It belongs to a class of drugs called alkylating agents, which work by damaging the DNA of cancer cells, preventing them from dividing and growing[2].

Medical Uses

Dacarbazine is primarily used in the treatment of:

  • Advanced Hodgkin Lymphoma: It is often used as part of combination chemotherapy regimens for patients with advanced-stage Hodgkin lymphoma[1].
  • Metastatic Melanoma: Dacarbazine is used in the treatment of unresectable or metastatic melanoma, particularly in cases where the cancer has a specific genetic mutation called NRAS[2].
  • Soft Tissue Sarcoma: It may be used as part of a combination therapy for certain types of soft tissue sarcomas[3].

How It Works

Dacarbazine is a prodrug, which means it needs to be activated in the body to become effective. Once activated, it works by:

  • Damaging the DNA of cancer cells
  • Interfering with cell division
  • Causing cancer cells to die

This mechanism of action helps to slow or stop the growth of cancer cells in the body[2].

Administration

Dacarbazine is typically administered in the following ways:

  • Intravenous (IV) infusion: The drug is given directly into a vein over a period of time[1].
  • Injection: In some cases, it may be given as an injection[2].

The method of administration will be determined by your healthcare provider based on your specific condition and treatment plan.

Dosage

The dosage of Dacarbazine can vary depending on the specific condition being treated, the patient’s body surface area, and other factors. Some general dosage information includes:

  • For advanced Hodgkin lymphoma, doses may range up to 375 mg/m² (milligrams per square meter of body surface area) per day[1].
  • For metastatic melanoma, doses may be up to 1000 mg/m² per day[2].
  • For soft tissue sarcoma, doses of up to 900 mg/m² per day have been used in clinical trials[3].

It’s important to note that these are general ranges, and your actual dosage will be determined by your healthcare provider.

Side Effects

Like all chemotherapy drugs, Dacarbazine can cause side effects. Common side effects may include:

  • Nausea and vomiting
  • Loss of appetite
  • Fatigue
  • Lowered blood cell counts, which can increase risk of infection or bleeding
  • Hair loss
  • Skin reactions

More serious side effects can occur, and it’s important to report any unusual symptoms to your healthcare provider immediately[2].

Precautions

Before receiving Dacarbazine, inform your healthcare provider if you:

  • Have any allergies
  • Have liver or kidney problems
  • Are pregnant or planning to become pregnant
  • Are breastfeeding
  • Have any other medical conditions

Dacarbazine can interact with other medications, so be sure to inform your doctor about all medications, supplements, and herbal products you are taking[2].

Ongoing Research

Dacarbazine continues to be studied in clinical trials, often in combination with other treatments. For example:

  • It is being investigated as part of a combination therapy for advanced Hodgkin lymphoma, alongside drugs like Brentuximab Vedotin[1].
  • In metastatic melanoma, it is being compared to newer targeted therapies and immunotherapies to determine the most effective treatment approaches[2].
  • For soft tissue sarcomas, researchers are studying its effectiveness as part of multi-drug chemotherapy regimens[3].

These ongoing studies aim to improve treatment outcomes and quality of life for patients with various types of cancer.

Aspect Details
Drug Name Dacarbazine Citrate
Drug Class Alkylating agent
Administration Intravenous infusion
Cancer Types Studied Advanced Hodgkin Lymphoma, Unresectable or Metastatic NRAS Mutant Cutaneous Melanoma, Soft Tissue Sarcoma
Trial Phases Phase II and Phase III
Key Endpoints Progression-Free Survival, Overall Survival, Safety and Tolerability
Dosage Range Varies by trial; up to 1000 mg/m² reported
Treatment Duration Varies by trial; up to 21 days per cycle reported
Combination Therapies Often studied in combination with other drugs (e.g., Brentuximab Vedotin, Trametinib)

Ongoing Clinical Trials on Dacarbazine Citrate

  • Study of pembrolizumab with drug combination for first-line treatment in patients with advanced-stage classic Hodgkin lymphoma

    Recruiting

    2 1 1 1
    Germany
  • Vusolimogene Oderparepvec with Nivolumab for Advanced Melanoma Patients Whose Cancer Progressed After Previous Immunotherapy Treatments

    Recruiting

    3 1 1 1
    Investigated diseases:
    France Germany Greece Italy Poland Spain
  • Study of Roginolisib for Patients with Advanced Uveal Melanoma

    Recruiting

    2 1 1 1
    Investigated diseases:
    Italy Spain
  • Study on the Effectiveness of Doxorubicin, Ifosfamide, and Dacarbazine in High-Risk Soft Tissue Sarcoma Patients

    Recruiting

    3 1 1 1
    Investigated diseases:
    France
  • Study Comparing Naporafenib and Trametinib Combination to Other Therapies for Patients with Previously Treated Unresectable or Metastatic NRAS Mutant Melanoma

    Not recruiting

    3 1 1 1
    Belgium Czechia Denmark France Germany Italy +4
  • Study on Early Response to Brentuximab Vedotin and Drug Combination for Advanced Hodgkin Lymphoma Patients

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Belgium Denmark The Netherlands Poland Portugal Slovakia +1

Glossary

  • Dacarbazine Citrate: A chemotherapy medication used to treat various types of cancer, particularly melanoma and Hodgkin lymphoma. It belongs to a class of drugs called alkylating agents.
  • Hodgkin Lymphoma: A type of cancer that affects the lymphatic system, which is part of the body's immune system. It is characterized by the presence of a specific type of cell called the Reed-Sternberg cell.
  • Melanoma: A type of skin cancer that develops from the pigment-producing cells known as melanocytes. It can occur anywhere on the body and is often associated with exposure to ultraviolet radiation from sunlight or tanning beds.
  • NRAS Mutation: A genetic alteration in the NRAS gene, which is involved in cell growth and division. NRAS mutations are found in some types of cancer, including melanoma, and can affect treatment options and prognosis.
  • Metastatic: Referring to cancer that has spread from its original site to other parts of the body.
  • Unresectable: Describing a tumor or cancer that cannot be completely removed through surgery, often due to its location or extent of spread.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening. It is an important measure of a treatment's effectiveness in clinical trials.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive. It is a key endpoint in many cancer clinical trials.
  • ECOG Performance Status: A scale used to assess how a patient's disease is progressing and how it affects daily living abilities. It ranges from 0 (fully active) to 5 (dead).
  • Alkylating Agent: A type of chemotherapy drug that works by damaging the DNA of cancer cells, preventing them from dividing and growing.

References

  1. http://clinicaltrials.eu/trial/study-on-early-response-to-brentuximab-vedotin-and-drug-combination-for-advanced-hodgkin-lymphoma-patients/
  2. http://clinicaltrials.eu/trial/study-comparing-naporafenib-and-trametinib-combination-to-other-therapies-for-patients-with-previously-treated-unresectable-or-metastatic-nras-mutant-melanoma/
  3. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-doxorubicin-ifosfamide-and-dacarbazine-in-high-risk-soft-tissue-sarcoma-patients/